Trial Condition(s):
Angina Pectoris, Postmenopause
Study to evaluate the effect of 1 mg Estradiol and 2 mg Drospirenone over 6 weeks on the coronary flow reserve of postmenopausal women with angina pectoris
Bayer Identifier:
90832
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
60
Trial Dates
Phase
2
Could I receive a placebo?
No
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
Double-blind, randomized, placebo-controlled, single center study to determine the effect of 1 mg estradiol and 2 mg drospirenone (1 tablet daily) over 6 weeks on the coronary flow reserve of post-menopausal women with angina pectoris measured by PET and echocardiography (ECHO)
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
